171 related articles for article (PubMed ID: 37932568)
21. Degarelix: a new approach for the treatment of prostate cancer.
Persson BE; Kold Olesen T; Jensen JK
Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
[TBL] [Abstract][Full Text] [Related]
22. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer.
Bryant AK; McKay RR; Kader AK; Parsons JK; Einck JP; Kane CJ; Mundt AJ; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1068-1076. PubMed ID: 30543857
[TBL] [Abstract][Full Text] [Related]
23. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.
Hopmans SN; Duivenvoorden WC; Werstuck GH; Klotz L; Pinthus JH
Urol Oncol; 2014 Nov; 32(8):1126-34. PubMed ID: 25242517
[TBL] [Abstract][Full Text] [Related]
24. Testosterone Recovery after Neoadjuvant Gonadotropin-Releasing Hormone Antagonist versus Agonist on Permanent Iodine-125 Seed Brachytherapy in Prostate Cancer Patients: A Propensity Score Analysis.
Iwata T; Maruyama Y; Kawada T; Sadahira T; Katayama S; Takamoto A; Sako T; Wada K; Edamura K; Kobayashi Y; Araki M; Watanabe M; Watanabe T; Nasu Y
Acta Med Okayama; 2021 Dec; 75(6):705-711. PubMed ID: 34955538
[TBL] [Abstract][Full Text] [Related]
25. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
26. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN; Woldu SL; Raj GV
Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
[TBL] [Abstract][Full Text] [Related]
27. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
[TBL] [Abstract][Full Text] [Related]
29. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F;
J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997
[TBL] [Abstract][Full Text] [Related]
30. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
[TBL] [Abstract][Full Text] [Related]
31. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Chen DY; Su PJ; See LC; Liu JR; Chuang CK; Pang ST; Tseng CN; Chen SW; Hsieh IC; Chu PH; Lin YC; Hsu CL; Chang JW; Lin MS; Pang JS; Hsieh MJ; Huang WK
Prostate; 2021 Sep; 81(12):902-912. PubMed ID: 34196430
[TBL] [Abstract][Full Text] [Related]
32. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE
BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.
Margel D; Peer A; Ber Y; Shavit-Grievink L; Tabachnik T; Sela S; Witberg G; Baniel J; Kedar D; Duivenvoorden WCM; Rosenbaum E; Pinthus JH
J Urol; 2019 Dec; 202(6):1199-1208. PubMed ID: 31188734
[TBL] [Abstract][Full Text] [Related]
34. Degarelix acetate for the treatment of prostate cancer.
Klotz L
Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136
[TBL] [Abstract][Full Text] [Related]
35. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
36. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.
Hosseini SA; Rajabi F; Akbari Sari A; Ayati M; Heidari S; Ghamary F
Med J Islam Repub Iran; 2016; 30():317. PubMed ID: 27390687
[TBL] [Abstract][Full Text] [Related]
37. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
38. Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.
Ueda T; Shiraishi T; Ito S; Ohashi M; Matsugasumi T; Yamada Y; Fujihara A; Hongo F; Okihara K; Ukimura O
Sci Rep; 2021 May; 11(1):10094. PubMed ID: 33980956
[TBL] [Abstract][Full Text] [Related]
39. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
